Uncoventional views on certain aspects of toxin-induced metabolic acidosis.

Man S Oh
Author Information
  1. Man S Oh: Department of Medicine, State University of New York, Downstate Medical Center, Brooklyn, New York, USA.

Abstract

This discussion will highlight the following 9 specific points that related to metabolic acidosis caused by various toxins. The current recommendation suggests that alcohol dehydrogenase inhibitor fomepizole is preferred to ethanol in treatment of methanol and ethylene glycol poisoning, but analysis of the enzyme kinetics indicates that ethanol is a better alternative. In the presence of a modest increase in serum osmolal gap (<30 mOsm/L), the starting dose of ethanol should be far less than the usual recommended dose. One can take advantage of the high vapor pressure of methanol in the treatment of methanol poisoning when hemodialysis is not readily available. Profuse sweating with increased water ingestion can be highly effective in reducing methanol levels. Impaired production of ammonia by the proximal tubule of the kidney plays a major role in the development of metabolic acidosis in pyroglutamic acidosis. Glycine, not oxalate, is the main final end product of ethylene glycol metabolism. Metabolism of ethylene glycol to oxalate, albeit important clinically, represents less than 1% of ethylene glycol disposal. Urine osmolal gap would be useful in the diagnosis of ethylene glycol poisoning, but not in methanol poisoning. Hemodialysis is important in the treatment of methanol poisoning and ethylene glycol poisoning with renal impairment, with or without fomepizole or ethanol treatment. Severe leucocytosis is a highly sensitive indicator of ethylene glycol poisoning. Uncoupling of oxidative phosphorylation by salicylate can explain most of the manifestations of salicylate poisoning.

Keywords

References

  1. Ann Emerg Med. 2009 Apr;53(4):439-450.e10 [PMID: 18639955]
  2. Biochem J. 1965 Oct;97(1):194-8 [PMID: 16749103]
  3. Biochem Pharmacol. 1964 Mar;13:319-36 [PMID: 14157591]
  4. Am J Physiol. 1997 Jan;272(1 Pt 1):C289-94 [PMID: 9038835]
  5. Arch Intern Med. 1986 Aug;146(8):1601-3 [PMID: 3729644]
  6. Pediatr Nephrol. 2008 Dec;23(12):2277-9 [PMID: 18696123]
  7. N Engl J Med. 2001 Feb 8;344(6):424-9 [PMID: 11172179]
  8. Ann Emerg Med. 2009 Apr;53(4):451-3 [PMID: 18986732]
  9. Toxicol Sci. 2005 Mar;84(1):195-200 [PMID: 15601675]
  10. West J Med. 1991 Dec;155(6):637-9 [PMID: 1812638]
  11. Am J Med. 1974 Jul;57(1):143-50 [PMID: 4834513]
  12. Diabetes. 1972 Sep;21(9):955-66 [PMID: 4626706]
  13. Vnitr Lek. 2002 Nov;48(11):1054-9 [PMID: 12577457]
  14. Hum Exp Toxicol. 2010 Feb;29(2):93-101 [PMID: 20026516]
  15. Can Med Assoc J. 1982 Jun 15;126(12):1391-4 [PMID: 7083094]
  16. Hum Exp Toxicol. 1994 Jan;13(1):61-4 [PMID: 8198831]
  17. J Vet Pharmacol Ther. 1985 Sep;8(3):254-62 [PMID: 4057346]
  18. Postgrad Med J. 1976 Sep;52(611):598-602 [PMID: 981106]
  19. Am J Med. 1988 Jan;84(1):145-52 [PMID: 3337119]
  20. Scand J Clin Lab Invest. 1976 Nov;36(7):649-54 [PMID: 1019575]
  21. Ann Emerg Med. 1995 Aug;26(2):202-7 [PMID: 7618784]
  22. J Clin Invest. 1970 Nov;49(11):2139-45 [PMID: 4319971]
  23. N Engl J Med. 1999 Mar 18;340(11):832-8 [PMID: 10080845]
  24. J Toxicol Clin Toxicol. 1987;25(1-2):95-108 [PMID: 3035205]
  25. J Toxicol Clin Toxicol. 2002;40(4):415-46 [PMID: 12216995]
  26. J Biol Phys. 2006 Oct;32(3-4):245-71 [PMID: 19669466]
  27. Acta Paediatr. 2007 Mar;96(3):461-3 [PMID: 17407481]
  28. Drug Metab Dispos. 1990 Nov-Dec;18(6):929-36 [PMID: 1981539]
  29. West J Med. 1985 Mar;142(3):337-40 [PMID: 3993008]
  30. Biochemistry. 1983 Apr 12;22(8):1857-63 [PMID: 6342669]
  31. Arch Toxicol. 1998 Sep;72(9):604-7 [PMID: 9806434]
  32. Postgrad Med J. 1982 Jul;58(681):454-6 [PMID: 7122395]
  33. JAMA. 1992 Jan 1;267(1):83-6 [PMID: 1727201]
  34. J Emerg Med. 1997 Sep-Oct;15(5):653-67 [PMID: 9348055]
  35. N Engl J Med. 1981 Jan 1;304(1):21-3 [PMID: 7432434]

Word Cloud

Created with Highcharts 10.0.0poisoningethyleneglycolmethanolacidosismetabolicethanoltreatmentosmolalgapcanfomepizoledoselesshighlyoxalateimportantsalicylatediscussionwillhighlightfollowing9specificpointsrelatedcausedvarioustoxinscurrentrecommendationsuggestsalcoholdehydrogenaseinhibitorpreferredanalysisenzymekineticsindicatesbetteralternativepresencemodestincreaseserum<30mOsm/LstartingfarusualrecommendedOnetakeadvantagehighvaporpressurehemodialysisreadilyavailableProfusesweatingincreasedwateringestioneffectivereducinglevelsImpairedproductionammoniaproximaltubulekidneyplaysmajorroledevelopmentpyroglutamicGlycinemainfinalendproductmetabolismMetabolismalbeitclinicallyrepresents1%disposalUrineusefuldiagnosisHemodialysisrenalimpairmentwithoutSevereleucocytosissensitiveindicatorUncouplingoxidativephosphorylationexplainmanifestationsUncoventionalviewscertainaspectstoxin-inducedtoxinurine

Similar Articles

Cited By